• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Editorial: Benign prostatic hyperplasia and overactive bladder: new members of metabolic syndrome.社论：良性前列腺增生与膀胱过度活动症：代谢综合征的新成员
Front Urol. 2023 Aug 25;3:1272592. doi: 10.3389/fruro.2023.1272592. eCollection 2023.
2
Comorbid Diabetes Mellitus Contributes to Residual Overactive Bladder After Transurethral Surgery for Benign Prostatic Hyperplasia.合并糖尿病会导致良性前列腺增生经尿道手术后残留的膀胱过度活动症。
Int J Urol. 2025 Aug;32(8):973-981. doi: 10.1111/iju.70080. Epub 2025 Apr 24.
3
Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia.神经生长因子水平与良性前列腺增生患者经尿道前列腺电切术后膀胱过度活动症症状及长期治疗结局相关。
J Urol. 2018 Sep;200(3):620-625. doi: 10.1016/j.juro.2018.03.130. Epub 2018 Apr 7.
4
Safety and efficacy of an α -blocker plus mirabegron compared with an α -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta-analysis.α 受体阻滞剂联合米拉贝隆与 α 受体阻滞剂联合抗胆碱能药物治疗良性前列腺增生伴膀胱过度活动症患者下尿路症状的安全性和有效性：系统评价和网络荟萃分析。
Neurourol Urodyn. 2024 Mar;43(3):604-619. doi: 10.1002/nau.25399. Epub 2024 Jan 30.
5
Evaluation and validation of the core lower urinary tract symptom score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: effects of the α1-adrenoreceptor antagonist silodosin.核心下尿路症状评分作为良性前列腺增生症治疗结局评估工具的评价与验证：α1-肾上腺素能受体拮抗剂西洛多辛的作用
Int J Urol. 2014 Jan;21(1):108-12. doi: 10.1111/iju.12167. Epub 2013 May 12.
6
Emerging links between non-neurogenic lower urinary tract symptoms secondary to benign prostatic obstruction, metabolic syndrome and its components: A systematic review.良性前列腺梗阻继发的非神经源性下尿路症状、代谢综合征及其组成成分之间的新联系：一项系统综述
Int J Urol. 2015 Nov;22(11):982-90. doi: 10.1111/iju.12877. Epub 2015 Jul 20.
7
Lower Urinary Tract Symptoms in Men: A Review.男性下尿路症状：综述
JAMA. 2025 Sep 2;334(9):809-821. doi: 10.1001/jama.2025.7045.
8
Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in men with benign prostatic hyperplasia and overactive bladder in a prospective randomized controlled trial.盆底磁刺激联合米拉贝隆治疗良性前列腺增生合并膀胱过度活动症男性患者的疗效和安全性：一项前瞻性随机对照试验
Am J Clin Exp Urol. 2025 Jun 15;13(3):215-224. doi: 10.62347/TMQG2381. eCollection 2025.
9
Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study).坦索罗辛、度他雄胺和咪达非那新联合治疗良性前列腺增生相关膀胱过度活动症症状的疗效和安全性：一项多中心、随机、开放标签、对照试验（直接研究）
Int J Urol. 2017 Jul;24(7):525-531. doi: 10.1111/iju.13359. Epub 2017 May 2.
10
[Expression of brainderived neurotrophic factor in urine of patients with benign prostatic hyperplasia complicated overactive bladder symptoms].[脑源性神经营养因子在良性前列腺增生合并膀胱过度活动症患者尿液中的表达]
Beijing Da Xue Xue Bao Yi Xue Ban. 2014 Aug 18;46(4):519-23.

引用本文的文献

1
Sustainable UV approaches backed by one step extraction procedure for quantifying the newly released mirabegron and silodosin mixture in urine.通过一步提取程序支持的可持续紫外线方法，用于定量尿液中新释放的米拉贝隆和西洛多辛混合物。
Sci Rep. 2025 Aug 14;15(1):29829. doi: 10.1038/s41598-025-13989-y.

Editorial: Benign prostatic hyperplasia and overactive bladder: new members of metabolic syndrome.

作者信息

Wang Xiaolong, Yu Qingfeng, Michel Martin C

机构信息

Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.

Department of Pathology and Laboratory Medicine, Temple University, Philadelphia, PA, United States.

出版信息

Front Urol. 2023 Aug 25;3:1272592. doi: 10.3389/fruro.2023.1272592. eCollection 2023.

DOI:10.3389/fruro.2023.1272592
PMID:40778039
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12327302/
Abstract
摘要